Clinical Data, Inc. company was founded in 1969 and is headquartered in Newton, Massachusetts. Clinical Data, Inc. operates as a global biotechnology company developing early and late stage targeted therapeutics, as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability, and efficacy. Its late-stage compounds include Vilazodone, a potential drug candidate for the treatment of depression, and Stedivaze, a potential cardiac stress agent. The company employs biomarker strategies and technologies to develop targeted therapeutics with advantages over existing treatments to help patients, healthcare professionals, and payers. Its PGxHealth division is leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability, and efficacy. PGxHealth built the commercial, managed care, and CLIA-certified laboratory infrastructure and capabilities to support its marketed tests, including the FAMILION family of genetic tests for inherited heart diseases and PGxPredict tests for predicting drug response. The company has a collaboration and licensing agreement with CombinatoRx Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma and other B-cell cancers.

Silence Therapeutics wants to put the kibosh on disease-causing genes. The company, formerly known as SR Pharma, is working in the field of RNA interference (RNAi), a cutting-edge approach to treating disease that involves interfering with, or silencing, targeted genes associated with disease. Its AtuPLEX drug delivery system is designed to work specifically with RNA molecules. Silence Therapeutics acquired fellow RNAi research company Intradigm in 2010, greatly expanding its RNAi program capabilities, which it hopes will make it a more attractive partner to bigger pharmaceutical companies looking to develop products based on that science.

BioSpecifics Technologies Corp. company was founded in 1957 and is headquartered in Lynbrook, New York. BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase for multiple indications in the United States. The company has a development and license agreement with Auxilium Pharmaceuticals, Inc. for injectable collagenase known as XIAFLEX for clinical indications in dupuytren's disease, peyronie's disease, and frozen shoulder. The XIAFLEX is under phase IIb clinical trial for the treatment of peyronie's disease. BioSpecifics Technologies also focuses on the development of collagenase for various other clinical indications, including lipomas and cellulite.

BioTrove, researchers can mine the treasure trove of information encoded in genetic material... and still make it home in time for dinner. The company makes the OpenArray life science research systems that allow scientists to rapidly prepare and test multiple genetic samples at once. The system can perform more than 3,000 genetic tests simultaneously on a single slide and is used by laboratory researchers in gene expression and genotyping analysis. BioTrove was acquired by Life Technologies in late 2009. At the same time, the company's RapidFire sample preparation business was spun off into a new entity named BIOCIUS Life Sciences.

4Life Research wants to protect the health of bipeds and quadrupeds alike. The multilevel marketing company manufactures nutritional supplements for humans and animals and sells them through its global network of independent distributors. The company's flagship product is Transfer Factor, a supplement made from egg yolks and cow colostrum that is meant to enhance the body's immune system. The firm makes Transfer Factor formulations for humans, dogs, cats, horses, and livestock. The privately-held company was founded in 1998 by CEO David Lisonbee, who had previous experience with multi-level marketing organizations.

Nycomed International Management GmbH the Swiss pharmaceutical company develops presciption and OTC medicines mainly focusing on cardiology, gastroenterology, osteoporosis, respiratory, and pain management therapies. It operates nearly 20 facilities in a dozen European countries, where it conducts its own research and drug testing. It also develops products in conjunction with partner pharmaceutical companies. The majority of Nycomed's revenues come from direct drug sales to doctors, hospitals, and pharmacies in Europe, the Americas, Russia, and Asia/Pacific as well as from licensing product rights to and from other companies.

Dendreon Corporation, formerly known as Activated Cell Therapy, Inc., was founded in 1992 and is headquartered in Seattle, Washington. Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that improve cancer treatment options for patients. Dendreon’s most advanced product candidate is Provenge (sipuleucel-T), an active cellular immunotherapy that has completed two Phase III trials for the treatment of asymptomatic, metastatic, androgen-independent prostate cancer.

VioQuest Pharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment. The Company’s lead compound under development is Xyfid (1% topical uracil) for the treatment and prevention of Hand-Foot Syndrome (HFS). In parallel, Xyfid is also being developed to treat dry skin conditions and manage the burning and itching associated with various diseases of the skin or dermatoses. In addition, VioQuest Pharmaceuticals is developing VQD-002 (triciribine phosphate monohydrate or TCN-P), a small molecule anticancer compound that inhibits activation of protein kinase B (PKB or AKT), a key component of a signaling pathway known to promote cancer cell growth and survival, as well as resistance to chemotherapy and radiotherapy. On July 16, 2007, the Company completed the sale of Chiral Quest, Inc. to Chiral Quest Acquisition Corp.

3SBio Inc. was founded in 1993 and is based in Shenyang, the Peoples Republic of China. 3SBio Inc. is an integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. The Company’s recombinant, or genetically engineered, protein-based products and product candidates are designed to address markets with unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. Its principal products are EPIAO and TPIAO, and its legacy products are Intefen and Inleusin. EPIAO is an injectable recombinant human erythropoietin (EPO) that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. 3SBio Inc. had launched TPIAO, its internally developed protein-based therapeutic product. In addition to EPIAO and TPIAO, the Company markets two other protein-based therapeutics.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The Company is developing a portfolio consisting of its four product candidates, including pimavanserin, which is in Phase III development for the treatment of Parkinson’s disease psychosis. In addition, the Company has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, Inc., and ACP-106 in IND-track development. The Company’s product candidates include Pimavanserin, AGN-XX/YY, AC-262271 and ACP-106. The Company maintains two wholly owned subsidiaries: ACADIA Pharmaceuticals AB based in Malmo, Sweden and ACADIA Pharmaceuticals A/S based in Denmark.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.